Specifically, COX-2 inhibition prevents the activation of antioxidant responses mediated by Nrf2 and Sp1, ultimately impairing the redox balance and sensitizing tumor cells to TMZ (Figure 7). The gene discussed is SP1; the disease is neoplasm.